Richard Miller

Company: Corvus Pharmaceuticals

Job title: Chief Executive Officer

Seminars:

Mupadolimab: A B Cell Activating Anti-CD73 Antibody for Immunotherapy of Cancer & Viral Diseases 2:15 pm

• Highlighting that Mupadolimab is a humanized anti CD73 antibody that activates B cells leading to expression of CD69, trafficking to lymph nodes and differentiation into antigen specific plasma cells and memory B cells • Demonstrating how the antibody has shown preliminary evidence of anti-tumor activity both as monotherapy and in combination with anti-PD1 in…Read more

day: Day Two